Antiviral research · 2018
Novel activities of safe-in-human broad-spectrum antiviral agents.
СтатьяПоддержка исследования: вне правительства СШАОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ianevski Aleksandr, Zusinaite Eva, Kuivanen Suvi, Strand Mårten, Lysvand Hilde, Teppor Mona, Kakkola Laura, Paavilainen Henrik, Laajala Mira, Kallio-Kokko Hannimari, Valkonen Miia, Kantele Anu, Telling Kaidi, Lutsar Irja, Letjuka Pille, Metelitsa Natalja, Oksenych Valentyn, Bjørås Magnar, Nordbø Svein Arne, Dumpis Uga, Vitkauskiene Astra, Öhrmalm Christina, Bondeson Kåre, Bergqvist Anders, Aittokallio Tero, Cox Rebecca J, Evander Magnus, Hukkanen Veijo, Marjomaki Varpu, Julkunen Ilkka, Vapalahti Olli, Tenson Tanel, Merits Andres, Kainov Denis
Аннотация
According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley fever virus. Thus, the spectrum of antiviral activities of existing antiviral agents could be expanded towards other viral diseases.